Mink therapeutics targets immune reconstitution to combat advanced gastroesophageal cancers with novel combination of allo-inkts plus bot/bal at asco gi

New york, jan. 23, 2025 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the american society of clinical oncology gastrointestinal cancers (asco gi) symposium in san francisco, california.
INKT Ratings Summary
INKT Quant Ranking